Ablynx Announces Technical Advances in its Nanobody(R) Platform Technology: Enhanced Benefits from Pulmonary Delivery and Half-Life Extension

-- Pulmonary delivery of anti-viral Nanobodies® gives extended protection against viral infection in vivo
-- In vivo proof of concept for its novel proprietary half-life extension technology

GHENT, BELGIUM | January 14, 2009 | Ablynx [Euronext Brussels: ABLX], a pioneer in the discovery and development of Nanobodies®, a novel class of antibody-derived therapeutic proteins, announced today two significant advances achieved with its Nanobody® platform. In the first, it has shown that anti-viral Nanobodies® give extended protection against viral infection in vivo when administered via an intrapulmonary route. In the second, Ablynx has demonstrated in vivo proof of concept for a proprietary novel half-life(*) extension technology which allows the half-life of its Nanobody®-based therapeutics to be tailored depending on the disease indication.

Pulmonary delivery of Nanobodies®

Ablynx has demonstrated that anti-viral Nanobodies® protect against signs of viral infection and presence of active virus when delivered via an intrapulmonary route. Following a single administration of the Nanobodies® via the lungs, neutralization of virus was observed for at least 72 hours.

Additionally, Ablynx has shown that Nanobodies® are suitable for systemic delivery(**) via the lungs. Their extended bioavailability is increased by a factor of five to ten times compared with intravenous administration.

Ablynx is also investigating other alternative delivery technologies for its Nanobodies® including oral to systemic delivery and needleless administration.

Novel proprietary half-life extension technology

Ablynx has access to several different methods to tailor the half-life of its Nanobodies® depending on the desired characteristics of the therapeutic drug candidate and the indication. The Company announced today that they have discovered and developed a novel proprietary half-life extension technology and demonstrated in vivo results which show considerable potential to significantly increase the half-life for its Nanobodies® in humans.

SOURCE: Ablynx:

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2021 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up

Top